CXL with MMC for Keratoconus

"There are currently 45 ongoing studies that focus on CXL with MMC. Out of these, 12 have reached Phase 3 clinical trials. Although many of the investigations related to this treatment are based in Bethesda, Maryland; there are 2070 locations running similar studies across the globe."

"Patients that meet the age requirement of 18-70 years old are eligible for this study. There are 21 other trials available for minors and 81 studies for patients older than 65."

"Yes, this information is available on clinicaltrials.gov. The trial was posted on 7/26/2021 and was last updated on 10/6/2021."

"64 individuals suffering from keratoconus, ranging in age from 18 to 70, are what this study require. Most importantly, potential candidates must meet the following two qualifications: They must be of either gender with confirmed progressive keratoconus or another ectatic disorder like post refractive surgery ectasia that is also progressing."

"CXL with MMC is a treatment for various diseases and cancers, including cervical cancer, lg-utuc, glaucoma, and mesotheliomas."

"CXL with MMC's safety is estimated to be a 2. This ranking comes from the fact that, while there has been some data supporting its safety, there is currently no information affirming its efficacy in Phase 2 of the trial."

"That is correct. The online information hosted on clinicaltrials.gov shows that this research trial is still recruiting patients. Originally, the study was posted on 26 July 2021 and has since been edited on 6 October 2021. Currently, the study is looking for 64 individuals who are willing to participate at 1 location."